Sector News

Report: Orphan drugs to nab 19% of drug sales by 2020–if payers don’t balk, that is

November 3, 2014
Life sciences
Pharma companies have been quick to get on board with the orphan drug development trend in recent years, racing to bring pricey treatments for small patient populations to market. And that trend won’t be going out of style anytime soon, a new report says.
 
Orphan drug sales will make up 19% of the total share of prescription drug sales by 2020, totaling $176 billion, according to Evaluate Pharma’s Orphan Drug Report 2014. And they’ll grow at an annual rate of nearly 11% per year through the end of the decade, compared with about 4% for drugs treating larger populations, EP predicts.
 
It’s easy to see why, the report’s authors note. Orphan drugs are cheaper to develop, in part because of tax incentives, and trial sizes are generally smaller. The lack of alternative treatments gives orphan drugs an edge in the regulatory review process, and it often keeps them free from generic competition, too. And then there’s the pricing power they command: On average, their cost per patient is 6 times that of non-orphan drugs, EP says.
 
Another reason orphan drug sales are set to soar: Bristol-Myers Squibb’s Opdivo. Behind just Celgene’s Revlimid, Bristol’s highly touted forthcoming treatment should finish with $6 billion in worldwide sales, EP’s forecasts say. That haul will help BMS pass Novartis to take the title for biggest orphan company by the time 2020 rolls around.
 
And with orphan drug designations for in-development products racking up faster than ever–the FDA granted a record 260 last year–“in all likelihood the number of orphan drugs that successfully complete the clinical and registration stages will be on the rise,” EP says.
 
But one thing could put a big damper on orphan therapies’ sales potential, and that’s payers. Though the pricing environment is favorable now, they’ll “be looking to manage escalating drug bills as patent expires slow in coming years,” EP points out.
 
That’s something they already have a head start on thanks to a new group of next-gen hepatitis C treatments. PBMs have already begun making moves to control costs–like Express Scripts, which this year began assembling a coalition to exclude Gilead’s $84,000-per-treatment-course Sovaldi until rival drugs hit the market and forced prices down.
 
By Carly Helfand
 

comments closed

Related News

October 10, 2021

Nutraceutical giants’ partnerships inject life back into industry at Vitafoods

Life sciences

Some of industry’s biggest players are joining forces to bring cost-effective yet scientifically backed offerings to the nutraceuticals market. Co-creation is reinvigorating supplement innovation, pairing together companies’ diverse expertise, sales networks and clinical trial investments.

October 10, 2021

Pilot launch complete: GlaxoSmithKline’s malaria shot scores WHO backing for wider rollout in Africa

Life sciences

GlaxoSmithKline has spent many years developing and testing its world-first malaria vaccine, but even after a positive recommendation from European regulators in 2015, the shot still isn’t widely deployed. That’s set to change with the World Health Organization’s (WHO’s) blessing for the vaccine.

October 10, 2021

Henrietta Lacks’ estate sues Thermo Fisher for continued sale of HeLa cells without family consent

Life sciences

A sample of Henrietta Lacks’ tissue was taken from her cervix without her consent while she was undergoing cancer treatment at Johns Hopkins Hospital in 1951. Her cells have subsequently been used to develop the polio vaccine, HPV vaccines and gene-mapping techniques and continue to be sold for research purposes by Thermo Fisher Scientific.

Send this to a friend